NRG Oncology

NRG Oncology
Name	NRG Oncology
Type	Clinical trials cooperative group
Headquarters	Philadelphia, Pennsylvania
Region served	United States
Leader title	Chief Executive Officer
Formation	2014
Predecessors	Radiation Therapy Oncology Group; Gynecologic Oncology Group; National Surgical Adjuvant Breast and Bowel Project

NRG Oncology is a United States-based clinical trials cooperative group focused on oncology clinical trials and translational research. It was created through a merger to consolidate expertise in radiation oncology, medical oncology, and surgical oncology and conducts phase I–III trials, outcomes research, and biomarker-driven studies. The organization works with academic cancer centers, hospitals, cooperative groups, and regulatory agencies to design and execute multicenter trials influencing standards of care for cancers such as breast, lung, prostate, gynecologic, and gastrointestinal malignancies.

History

NRG Oncology was formed in 2014 from the consolidation of three major cooperative groups: the Radiation Therapy Oncology Group, the Gynecologic Oncology Group, and the National Surgical Adjuvant Breast and Bowel Project. The merger followed shifting priorities in U.S. federal research funding and recommendations from the Institute of Medicine regarding clinical trials networks. Its creation aligned with initiatives from the National Cancer Institute to streamline the National Clinical Trials Network and improve efficiency across cooperative groups such as Alliance for Clinical Trials in Oncology and SWOG Cancer Research Network. Early leadership included investigators with prior roles at institutions like Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Dana-Farber Cancer Institute. Over time, NRG integrated legacy trial portfolios from predecessor groups, adapting protocols influenced by regulatory guidance from the Food and Drug Administration and methodological frameworks from the European Organisation for Research and Treatment of Cancer.

Organization and governance

Governance is structured through committees and elected leadership including a board of investigators, protocol committees, and scientific subcommittees with representation from academic centers such as Johns Hopkins Hospital, Mayo Clinic, and University of California, San Francisco Medical Center. Administrative oversight is coordinated with the ECOG-ACRIN Cancer Research Group and Alliance for Clinical Trials in Oncology for cross-group operations under the National Cancer Institute framework. Institutional Review Boards at participating sites including Cleveland Clinic and Barnes-Jewish Hospital review protocols. The operational model incorporates data management from cooperative entities like the Cancer Trials Support Unit and statistical centers modeled after practices at the Fred Hutchinson Cancer Research Center.

Clinical trial programs

NRG conducts randomized phase II and III trials across tumor types, building on trial traditions from the predecessor groups such as adjuvant studies from NSABP-era work and radiation trials from the Radiation Therapy Oncology Group. Notable trial portfolios include investigations in breast cancer influenced by trials at St. George's Hospital style cooperative networks, lung cancer trials comparable in scope to those at Royal Marsden Hospital consortia, and gynecologic cancer trials reflecting Gynecologic Oncology Group legacies. Trials often evaluate combinations of radiotherapy, systemic agents, and surgical approaches, with endpoints and designs informed by guidance from the American Society of Clinical Oncology and statistical methodologies comparable to those used at the University of Oxford clinical trials unit.

Research areas and contributions

Research spans radiotherapy technique optimization, chemoradiation regimens, biomarker validation, and health outcomes research. Investigations include image-guided radiotherapy studies akin to efforts at Massachusetts General Hospital and radiobiology collaborations reflecting work from European Society for Radiotherapy and Oncology investigators. Biomarker-driven protocols engage translational science approaches similar to projects at Broad Institute and Salk Institute, incorporating molecular profiling used at Johns Hopkins University School of Medicine and genomic annotation practices from The Cancer Genome Atlas consortium. Contributions have informed practice-changing guidelines referenced by societies such as the American Society for Radiation Oncology and influenced staging or treatment recommendations considered by panels at the National Comprehensive Cancer Network.

Collaborations and partnerships

NRG partners with cooperative groups including Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and SWOG Cancer Research Network within the National Clinical Trials Network. It collaborates with pharmaceutical companies such as Genentech, Pfizer, and Merck on investigator-initiated and industry-sponsored trials, and with academic consortia including Cancer Research UK-affiliated groups and the European Organisation for Research and Treatment of Cancer on international protocols. Data-sharing and biobanking partnerships mirror models used by organizations like Project Data Sphere and engage central laboratories similar to those at ARUP Laboratories.

Funding and affiliations

Primary funding sources include grants administered by the National Cancer Institute under cooperative agreement mechanisms, supplemented by philanthropic support from foundations such as the American Cancer Society and industry-sponsored trial support from pharmaceutical firms. Affiliate institutions include major cancer centers like Yale Cancer Center and Stanford Cancer Institute, and research support infrastructure aligns with services from entities such as the Clinical Trials Transformation Initiative and the Office for Human Research Protections.

Impact and outcomes

NRG trials have contributed to changes in standard-of-care treatments, influencing practice in areas such as adjuvant breast radiotherapy, definitive chemoradiation for lung cancer, and management of gynecologic malignancies. Results from NRG-affiliated protocols have appeared in journals where research from The Lancet Oncology, Journal of Clinical Oncology, and New England Journal of Medicine is commonly cited, and findings have been presented at meetings of the American Society of Clinical Oncology, European Society for Medical Oncology, and American Association for Cancer Research. Cumulative outcomes include improved survival metrics, refined radiotherapy techniques adopted at centers like UCSF Medical Center, and validated biomarkers that guide personalized treatment decisions at institutions such as Memorial Sloan Kettering Cancer Center.

Category:Clinical trials organizations